Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05933187 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants
A Phase 1 study, sponsored by Cerevel Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT05933187 is a Phase 1 study that has completed, run by Cerevel Therapeutics. The registered enrollment target is 15 participants.
The verdict
NCT05933187, a Phase 1 study, has completed, sponsored by Cerevel Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate plasma concentrations of emraclidine following single dose oral administration of different emraclidine immediate release (IR) tablets in healthy participants.
Interventions
- DRUG Treatment A: Emraclidine 30mg IR tablets (reference)
- DRUG Treatment B: Emraclidine 30mg IR test tablets 1
- DRUG Treatment C: Emraclidine 30mg IR test tablets 2
- DRUG Treatment D: Emraclidine 30mg IR test tablets 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2023-07-19 |
| Est. Completion | 2023-09-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05933187
The ClinicalTrials.gov registry entry for NCT05933187 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cerevel Therapeutics, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Treatment A: Emraclidine 30mg IR tablets (reference) is the first listed.
NCT05933187 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05933187 about?
NCT05933187 is a clinical study titled "A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants". The purpose of this trial is to evaluate plasma concentrations of emraclidine following single dose oral administration of different emraclidine immediate release (IR) tablets in healthy participants.
What is the current status of trial NCT05933187?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2023-07-19. Estimated completion is 2023-09-12.
What interventions are being tested in trial NCT05933187?
The interventions under investigation include: Treatment A: Emraclidine 30mg IR tablets (reference) (DRUG), Treatment B: Emraclidine 30mg IR test tablets 1 (DRUG), Treatment C: Emraclidine 30mg IR test tablets 2 (DRUG), Treatment D: Emraclidine 30mg IR test tablets 3 (DRUG).
Who is sponsoring clinical trial NCT05933187?
This trial is sponsored by Cerevel Therapeutics, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.